;PMID: 118814
;source_file_1011.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..50] = [t:0..50]
;1)sentence:[e:56..174] = [t:56..174]
;2)section:[e:178..197] = [t:178..197]
;3)section:[e:201..272] = [t:201..272]
;4)sentence:[e:276..466] = [t:276..466]
;5)sentence:[e:467..618] = [t:467..618]
;6)sentence:[e:619..711] = [t:619..711]
;7)sentence:[e:712..787] = [t:712..787]
;8)sentence:[e:788..843] = [t:788..843]
;9)sentence:[e:844..996] = [t:844..996]
;10)sentence:[e:997..1062] = [t:997..1062]
;11)sentence:[e:1063..1117] = [t:1063..1117]
;12)section:[e:1121..1164] = [t:1121..1164]

;section 0 Span:0..50
;C R Seances Acad Sci D. 1979 Nov 5;289(11):777-80.
(SEC
  (FRAG (NNP:[0..1] C) (NNP:[2..3] R) (NNP:[4..11] Seances) (NNP:[12..16] Acad)
        (NNP:[17..20] Sci) (NNP:[21..23] D.) (CD:[24..28] 1979)
        (NNP:[29..32] Nov) (CC:[33..39] 5;289-LRB-) (CD:[39..41] 11)
        (-RRB-:[41..42] -RRB-) (CD:[42..46] :777) (::[46..47] -)
        (CD:[47..49] 80) (.:[49..50] .)))

;sentence 1 Span:56..174
;[Demonstration of "hydroxylase" and "epoxide hydrase" activities in
;preparations  of nucleoli isolated from rat liver]
;[75..86]:substance:"hydroxylase"
;[93..108]:substance:"epoxide hydrase"
(SENT
  (NP-HLN (-LRB-:[56..57] -LSB-)
    (NP (NN:[57..70] Demonstration))
    (PP (IN:[71..73] of)
      (NP
        (NP (``:[74..75] ") (NN:[75..86] hydroxylase) ('':[86..87] ")
          (NML-1 (-NONE-:[87..87] *P*)))
        (CC:[88..91] and)
        (NP (``:[92..93] ")
           (NN:[93..100] epoxide) (NN:[101..108] hydrase)
          ('':[108..109] ")
          (NML-1 (NNS:[110..120] activities)))))
    (PP (IN:[121..123] in)
      (NP
        (NP (NNS:[124..136] preparations))
        (PP (IN:[138..140] of)
          (NP
            (NP (NNS:[141..149] nucleoli))
            (VP (VBN:[150..158] isolated)
              (NP (-NONE-:[158..158] *))
              (PP (IN:[159..163] from)
                (NP (NN:[164..167] rat) (NN:[168..173] liver))))))))
    (-RRB-:[173..174] -RSB-)))

;section 2 Span:178..197
;[Article in French]
(SEC
  (FRAG (NN:[178..186] -LSB-Article) (IN:[187..189] in) (JJ:[190..196] French)
        (NNS:[196..197] -RSB-)))

;section 3 Span:201..272
;Lafarge-Frayssinet C, Alexandrov K, Dansette P, Guerry R, Frayssinet C.
(SEC
  (FRAG (NNP:[201..208] Lafarge) (::[208..209] -) (NNP:[209..219] Frayssinet)
        (NNP:[220..221] C) (,:[221..222] ,) (NNP:[223..233] Alexandrov)
        (NNP:[234..235] K) (,:[235..236] ,) (NNP:[237..245] Dansette)
        (NNP:[246..247] P) (,:[247..248] ,) (NNP:[249..255] Guerry)
        (NNP:[256..258] R,) (NNP:[259..269] Frayssinet) (NNP:[270..272] C.)))

;sentence 4 Span:276..466
;Aryl hydrocarbon hydroxylase (AHH) activity and epoxyde hydrase (EH) activity
; have been found in Rat liver nucleoli obtained from untreated (C) and 
;methylcholanthrene (MC) pretreated Rats.
;[276..304]:substance:"Aryl hydrocarbon hydroxylase"
;[306..309]:substance:"AHH"
;[324..339]:substance:"epoxyde hydrase"
;[341..343]:substance:"EH"
;[426..444]:substance:"methylcholanthrene"
;[446..448]:substance:"MC"
(SENT
  (S
    (NP-SBJ-2
      (NP
        (NML
          (NML (NN:[276..280] Aryl) (NN:[281..292] hydrocarbon)
               (NN:[293..304] hydroxylase))
          (NML (-LRB-:[305..306] -LRB-) (NN:[306..309] AHH)
               (-RRB-:[309..310] -RRB-)))
        (NN:[311..319] activity))
      (CC:[320..323] and)
      (NP
        (NML
          (NML (NN:[324..331] epoxyde) (NN:[332..339] hydrase))
          (NML (-LRB-:[340..341] -LRB-) (NN:[341..343] EH)
               (-RRB-:[343..344] -RRB-)))
        (NN:[345..353] activity)))
    (VP (VBP:[355..359] have)
      (VP (VBN:[360..364] been)
        (VP (VBN:[365..370] found)
          (NP-2 (-NONE-:[370..370] *))
          (PP-LOC (IN:[371..373] in)
            (NP
              (NP (NN:[374..377] Rat) (NN:[378..383] liver)
                  (NNS:[384..392] nucleoli))
              (VP (VBN:[393..401] obtained)
                (NP (-NONE-:[401..401] *))
                (PP (IN:[402..406] from)
                  (NP
                    (NP
                      (NML
                        (NML (JJ:[407..416] untreated))
                        (NML (-LRB-:[417..418] -LRB-) (NN:[418..419] C)
                             (-RRB-:[419..420] -RRB-)))
                      (NML-1 (-NONE-:[420..420] *P*)))
                    (CC:[421..424] and)
                    (NP
                      (ADJP
                        (NML
                          (NML (NN:[426..444] methylcholanthrene))
                          (NML (-LRB-:[445..446] -LRB-) (NN:[446..448] MC)
                               (-RRB-:[448..449] -RRB-)))
                        (VBN:[450..460] pretreated))
                      (NML-1 (NNS:[461..465] Rats)))))))))))
    (.:[465..466] .)))

;sentence 5 Span:467..618
;Electron microscopic observations of  nucleolar preparations did not reveal
;significant contamination either by intact  nuclei or by nuclear membranes.
(SENT
  (S
    (NP-SBJ
      (NP (NN:[467..475] Electron) (JJ:[476..487] microscopic)
          (NNS:[488..500] observations))
      (PP (IN:[501..503] of)
        (NP (JJ:[505..514] nucleolar) (NNS:[515..527] preparations))))
    (VP (VBD:[528..531] did) (RB:[532..535] not)
      (VP (VB:[536..542] reveal)
        (NP
          (NP (JJ:[543..554] significant) (NN:[555..568] contamination))
          (PP (CC:[569..575] either)
            (PP (IN:[576..578] by)
              (NP (JJ:[579..585] intact) (NNS:[587..593] nuclei)))
            (CC:[594..596] or)
            (PP (IN:[597..599] by)
              (NP (JJ:[600..607] nuclear) (NNS:[608..617] membranes)))))))
    (.:[617..618] .)))

;sentence 6 Span:619..711
;Very low but detectable activity of NADPH  cytochrome C reductase was found
;in the nucleoli.
;[655..660]:substance:"NADPH"
;[662..684]:substance:"cytochrome C reductase"
(SENT
  (S
    (NP-SBJ-1
      (NP
        (NP
          (ADJP (RB:[619..623] Very) (JJ:[624..627] low))
          (NML-2 (-NONE-:[627..627] *P*)))
        (CC:[628..631] but)
        (NP
          (ADJP (JJ:[632..642] detectable))
          (NML-2 (NN:[643..651] activity))))
      (PP (IN:[652..654] of)
        (NP (NN:[655..660] NADPH)
          
          (NML (NN:[662..672] cytochrome) (NN:[673..674] C))
          (NN:[675..684] reductase))))
    (VP (VBD:[685..688] was)
      (VP (VBN:[689..694] found)
        (NP-1 (-NONE-:[694..694] *))
        (PP-LOC (IN:[695..697] in)
          (NP (DT:[698..701] the) (NNS:[702..710] nucleoli)))))
    (.:[710..711] .)))

;sentence 7 Span:712..787
;Nucleolar preparations  revealed little AHH activity (12-18 pmoles/min/mg).
;[752..755]:substance:"AHH"
;[766..771]:quantitative-value:"12-18"
;[772..785]:quantitative-units:"pmoles/min/mg"
(SENT
  (S
    (NP-SBJ (JJ:[712..721] Nucleolar) (NNS:[722..734] preparations))
    (VP (VBD:[736..744] revealed)
      (NP (JJ:[745..751] little) (NN:[752..755] AHH) (NN:[756..764] activity)
        (PRN (-LRB-:[765..766] -LRB-)
          (NP
            (NP
              (QP (CD:[766..768] 12) (HYPH:[768..769] -) (CD:[769..771] 18))
              (NNS:[772..778] pmoles))
            (PP (SYM:[778..779] /)
              (NP (NN:[779..782] min)))
            (PP (SYM:[782..783] /)
              (NP (NN:[783..785] mg))))
          (-RRB-:[785..786] -RRB-))))
    (.:[786..787] .)))

;sentence 8 Span:788..843
;AHH was inducible by MC in  nuclei but not in nucleoli.
;[788..791]:substance:"AHH"
;[809..811]:substance:"MC"
(SENT
  (S
    (NP-SBJ (NN:[788..791] AHH))
    (VP
      (VP (VBD:[792..795] was)
        (NP-PRD
          (NP (JJ:[796..805] inducible))
          (PP (IN:[806..808] by)
            (NP (NN:[809..811] MC)))
          (PP-LOC=1 (IN:[812..814] in)
            (NP (NNS:[816..822] nuclei)))))
      (CC:[823..826] but) (RB:[827..830] not)
      (VP
        (PP-LOC=1 (IN:[831..833] in)
          (NP (NNS:[834..842] nucleoli)))))
    (.:[842..843] .)))

;sentence 9 Span:844..996
;The presence of EH in nucleoli was demonstrated with  phenanthrene 9,10-oxide
;(550-620 pmoles/min/mg) and benzopyrene 4,5-oxide  (92-116 pmoles/min/mg).
;[860..862]:substance:"EH"
;[898..921]:substance:"phenanthrene 9,10-oxide"
;[923..930]:quantitative-value:"550-620"
;[931..944]:quantitative-units:"pmoles/min/mg"
;[950..971]:substance:"benzopyrene 4,5-oxide"
;[974..980]:quantitative-value:"92-116"
;[981..994]:quantitative-units:"pmoles/min/mg"
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[844..847] The) (NN:[848..856] presence))
      (PP (IN:[857..859] of)
        (NP (NN:[860..862] EH)))
      (PP-LOC (IN:[863..865] in)
        (NP (NNS:[866..874] nucleoli))))
    (VP (VBD:[875..878] was)
      (VP (VBN:[879..891] demonstrated)
        (NP-1 (-NONE-:[891..891] *))
        (PP (IN:[892..896] with)
          (NP
            (NP
               (NN:[898..910] phenanthrene) (NN:[911..921] 9,10-oxide)
              (PRN (-LRB-:[922..923] -LRB-)
                (NP
                  (NP
                    (QP (CD:[923..926] 550) (HYPH:[926..927] -)
                        (CD:[927..930] 620))
                    (NNS:[931..937] pmoles))
                  (PP (SYM:[937..938] /)
                    (NP (NN:[938..941] min)))
                  (PP (SYM:[941..942] /)
                    (NP (NN:[942..944] mg))))
                (-RRB-:[944..945] -RRB-)))
            (CC:[946..949] and)
            (NP
               (NN:[950..961] benzopyrene) (NN:[962..971] 4,5-oxide)
              (PRN (-LRB-:[973..974] -LRB-)
                (NP
                  (NP
                    (QP (CD:[974..976] 92) (HYPH:[976..977] -)
                        (CD:[977..980] 116))
                    (NNS:[981..987] pmoles))
                  (PP (SYM:[987..988] /)
                    (NP (NN:[988..991] min)))
                  (PP (SYM:[991..992] /)
                    (NP (NN:[992..994] mg))))
                (-RRB-:[994..995] -RRB-)))))))
    (.:[995..996] .)))

;sentence 10 Span:997..1062
;These values were lower than those obtained using intact  nuclei.
(SENT
  (S
    (NP-SBJ (DT:[997..1002] These) (NNS:[1003..1009] values))
    (VP (VBD:[1010..1014] were)
      (ADJP-PRD
        (ADJP (JJR:[1015..1020] lower))
        (PP (IN:[1021..1025] than)
          (NP
            (NP (DT:[1026..1031] those))
            (VP (VBN:[1032..1040] obtained)
              (NP (-NONE-:[1040..1040] *))
              (S-MNR
                (NP-SBJ (-NONE-:[1040..1040] *))
                (VP (VBG:[1041..1046] using)
                  (NP (JJ:[1047..1053] intact) (NNS:[1055..1061] nuclei)))))))))
    (.:[1061..1062] .)))

;sentence 11 Span:1063..1117
;The addition of TCPO (10(-4) M) inhibited EH activity.
;[1079..1083]:substance:"TCPO"
;[1085..1091]:quantitative-value:"10(-4)"
;[1092..1093]:quantitative-units:"M"
;[1105..1107]:substance:"EH"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[1063..1066] The) (NN:[1067..1075] addition))
      (PP (IN:[1076..1078] of)
        (NP (NN:[1079..1083] TCPO)
          (PRN (-LRB-:[1084..1085] -LRB-)
            (NP (CD:[1085..1091] 10-LRB--4-RRB-) (NN:[1092..1093] M))
            (-RRB-:[1093..1094] -RRB-)))))
    (VP (VBD:[1095..1104] inhibited)
      (NP (NN:[1105..1107] EH) (NN:[1108..1116] activity)))
    (.:[1116..1117] .)))

;section 12 Span:1121..1164
;PMID: 118814 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1121..1125] PMID) (::[1125..1126] :) (CD:[1127..1133] 118814)
        (NN:[1134..1135] -LSB-) (NNP:[1135..1141] PubMed) (::[1142..1143] -)
        (NN:[1144..1151] indexed) (IN:[1152..1155] for)
        (NNP:[1156..1164] MEDLINE-RSB-)))
